Reviewing Cellectis S.A. (CLLS)’s and Magenta Therapeutics Inc. (NASDAQ:MGTA)’s results – MS Wkly

As Biotechnology businesses, Cellectis S.A. (NASDAQ:CLLS) and Magenta Therapeutics Inc. (NASDAQ:MGTA), are affected by compare. This especially applies to their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation

Table 1 showcases the gross revenue, earnings per share and valuation of Cellectis S.A. and Magenta Therapeutics Inc.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Liquidity

9.8 and 9.7 are the respective Current Ratio and a Quick Ratio of Cellectis S.A. Its rival Magenta Therapeutics Inc.s Current and Quick Ratios are 17.1 and 17.1 respectively. Magenta Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Cellectis S.A.

Insider and Institutional Ownership

Cellectis S.A. and Magenta Therapeutics Inc. has shares held by institutional investors as follows: 31.4% and 85.4%. Insiders Competitively, held 2.2% of Magenta Therapeutics Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Cellectis S.A. had bearish trend while Magenta Therapeutics Inc. had bullish trend.

Summary

Cellectis S.A. beats Magenta Therapeutics Inc. on 7 of the 9 factors.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companys products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more:
Reviewing Cellectis S.A. (CLLS)'s and Magenta Therapeutics Inc. (NASDAQ:MGTA)'s results - MS Wkly